Effects of Quinidine on the Action Potential Duration Restitution Property in the Right Ventricular Outflow Tract in Patients With Brugada Syndrome
スポンサーリンク
概要
- 論文の詳細を見る
Background: On a cellular level, Brugada syndrome has been attributed to a deep phase 1 notch and subsequent shallow and prolonged repolarization in the right ventricular outflow tract (RVOT). A sodium channel mutation that leads to early inactivation of the late sodium current has been identified in some patients. Thus, drugs that inhibit the transient outward current (Ito) responsible for the phase 1 notch and/or enhance the late sodium current might suppress arrhythmic events in patients with Brugada syndrome. The effects of quinidine gluconate, a potent inhibitor of Ito, on RVOT action potential duration (APD) restitution kinetics in patients with Brugada syndrome were evaluated. Methods and Results: Programmed ventricular stimulation was performed in 9 Brugada syndrome patients by delivering up to 3 extrastimuli from the right ventricular apex and RVOT. RVOT monophasic action potentials (MAPs) were recorded before and after intravenous administration of quinidine (n=6) or ibutilide (n=3). All patients had inducible ventricular fibrillation (VF) before drug administration. Both quinidine and ibutilide increased steady-state and minimum RVOT MAP duration during programmed stimulation. Quinidine decreased the maximum slope of the RVOT APD restitution curve and VF could not be induced after administration of quinidine in 5 of the 6 patients. Conclusions: Quinidine appears to suppress the induction of VF by increasing RVOT MAP duration and decreasing the maximum slope of the restitution curve. (Circ J 2011; 75: 2080-2086)
論文 | ランダム
- 卵巣癌の予後に関わるNO合成酵素の意義(第100群 卵巣腫瘍8)
- 培養肺胞II型上皮細胞RLE-6TNにおけるFITC-アルブミンのクラスリン介在型エンドサイトーシス(発表論文抄録(2006))
- わが国および欧米におけるブロー氏液(酢酸アルミニウム溶液)の処方に関する比較検討と提言
- 各種癌細胞株における胎盤由来蛋白Annexin Vの発現機構に関する検討(第44群 悪性腫瘍全般2)
- P-235 院内製剤ブロー氏液およびその関連溶液の抗真菌作用(11.院内製剤(薬局製剤)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)